-
A Seamless Phase II/III Design with Dose Optimization for Oncology Drug Development
Authors:
Yuhan Li,
Yiding Zhang,
Gu Mi,
Ji Lin
Abstract:
The US FDA's Project Optimus initiative that emphasizes dose optimization prior to marketing approval represents a pivotal shift in oncology drug development. It has a ripple effect for rethinking what changes may be made to conventional pivotal trial designs to incorporate a dose optimization component. Aligned with this initiative, we propose a novel Seamless Phase II/III Design with Dose Optimi…
▽ More
The US FDA's Project Optimus initiative that emphasizes dose optimization prior to marketing approval represents a pivotal shift in oncology drug development. It has a ripple effect for rethinking what changes may be made to conventional pivotal trial designs to incorporate a dose optimization component. Aligned with this initiative, we propose a novel Seamless Phase II/III Design with Dose Optimization (SDDO framework). The proposed design starts with dose optimization in a randomized setting, leading to an interim analysis focused on optimal dose selection, trial continuation decisions, and sample size re-estimation (SSR). Based on the decision at interim analysis, patient enrollment continues for both the selected dose arm and control arm, and the significance of treatment effects will be determined at final analysis. The SDDO framework offers increased flexibility and cost-efficiency through sample size adjustment, while stringently controlling the Type I error. This proposed design also facilitates both Accelerated Approval (AA) and regular approval in a "one-trial" approach. Extensive simulation studies confirm that our design reliably identifies the optimal dosage and makes preferable decisions with a reduced sample size while retaining statistical power.
△ Less
Submitted 31 May, 2024;
originally announced June 2024.
-
A Multi-Arm Two-Stage (MATS) Design for Proof-of-Concept and Dose Optimization in Early-Phase Oncology Trials
Authors:
Zhenghao Jiang,
Gu Mi,
Ji Lin,
Christelle Lorenzato,
Yuan Ji
Abstract:
The Project Optimus initiative by the FDA's Oncology Center of Excellence is widely viewed as a groundbreaking effort to change the $\textit{status quo}$ of conventional dose-finding strategies in oncology. Unlike in other therapeutic areas where multiple doses are evaluated thoroughly in dose ranging studies, early-phase oncology dose-finding studies are characterized by the practice of identifyi…
▽ More
The Project Optimus initiative by the FDA's Oncology Center of Excellence is widely viewed as a groundbreaking effort to change the $\textit{status quo}$ of conventional dose-finding strategies in oncology. Unlike in other therapeutic areas where multiple doses are evaluated thoroughly in dose ranging studies, early-phase oncology dose-finding studies are characterized by the practice of identifying a single dose, such as the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D). Following the spirit of Project Optimus, we propose an Multi-Arm Two-Stage (MATS) design for proof-of-concept (PoC) and dose optimization that allows the evaluation of two selected doses from a dose-escalation trial. The design assess the higher dose first across multiple indications in the first stage, and adaptively enters the second stage for an indication if the higher dose exhibits promising anti-tumor activities. In the second stage, a randomized comparison between the higher and lower doses is conducted to achieve proof-of-concept (PoC) and dose optimization. A Bayesian hierarchical model governs the statistical inference and decision making by borrowing information across doses, indications, and stages. Our simulation studies show that the proposed MATS design yield desirable performance. An R Shiny application has been developed and made available at https://matsdesign.shinyapps.io/mats/.
△ Less
Submitted 12 April, 2023;
originally announced April 2023.
-
Double Higgs production in the littlest Higgs Model with T-parity at high energy $e^{+}e^{-}$ Colliders
Authors:
Bingfang Yang,
Guofa Mi,
Ning Liu
Abstract:
In the framework of the littlest Higgs model with T-parity(LHT), we investigate the double Higgs production processes $e^{+}e^{-}\rightarrow ZHH$ and $e^{+}e^{-}\rightarrow ν\barνHH$ at high energy $e^{+}e^{-}$ colliders. We calculate the production cross sections and find that the relative correction at the center-of-mass energy $\sqrt{s}=500$ GeV can maximally reach $-30%$ for the process…
▽ More
In the framework of the littlest Higgs model with T-parity(LHT), we investigate the double Higgs production processes $e^{+}e^{-}\rightarrow ZHH$ and $e^{+}e^{-}\rightarrow ν\barνHH$ at high energy $e^{+}e^{-}$ colliders. We calculate the production cross sections and find that the relative correction at the center-of-mass energy $\sqrt{s}=500$ GeV can maximally reach $-30%$ for the process $e^{+}e^{-}\rightarrow ZHH$ and $-16%$ for the process $e^{+}e^{-}\rightarrow ν\barνHH$ in the allowed parameter space, respectively. These large relative corrections can reach the detection range of the future $e^{+}e^{-}$ colliders so that they can be used to test the LHT effect. The two relevant decay modes $e^{+}e^{-}\rightarrow ZHH \rightarrow l\bar{l} b\bar{b}b\bar{b}$ and $e^{+}e^{-}\rightarrow ν\barνHH\rightarrow ν\barνb\bar{b}b\bar{b}$ are studied and some distributions of the signal and background are displayed.
△ Less
Submitted 14 December, 2014; v1 submitted 19 August, 2014;
originally announced August 2014.
-
Higgs couplings and Naturalness in the littlest Higgs model with T-parity at the LHC and TLEP
Authors:
Bingfang Yang,
Guofa Mi,
Ning Liu
Abstract:
Motivated by the recent LHC Higgs data and null results in searches for any new physics, we investigate the Higgs couplings and naturalness in the littlest Higgs model with T-parity. By performing the global fit of the latest Higgs data, electroweak precise observables and $R_{b}$ measurements, we find that the scale $f$ can be excluded up to 600 GeV at $2σ$ confidence level. The expected Higgs co…
▽ More
Motivated by the recent LHC Higgs data and null results in searches for any new physics, we investigate the Higgs couplings and naturalness in the littlest Higgs model with T-parity. By performing the global fit of the latest Higgs data, electroweak precise observables and $R_{b}$ measurements, we find that the scale $f$ can be excluded up to 600 GeV at $2σ$ confidence level. The expected Higgs coupling measurements at the future collider TLEP will improve this lower limit to above 3 TeV. Besides, the top parnter mass $m_{T_{+}}$ can be excluded up to 880 GeV at $2σ$ confidence level. The future HL-LHC can constrain this mass in the region $m_{T_{+}} < 2.2$ TeV corresponding to the fine-tuning being lager than 1%.
△ Less
Submitted 23 September, 2014; v1 submitted 23 July, 2014;
originally announced July 2014.
